. 2004 Jun;42(6):2733–2741. doi: 10.1128/JCM.42.6.2733-2741.2004

TABLE 2.

Diagnosis of IA and its documentation

Episode no.	Patient characteristics^a:						Host factors	Clinical evidence	Culture and its source	Histological evidence	Maximum value (method I/method II)
Episode no.	Age (yr)	Sex	IA	Primary disease	Status of primary disease	Out- come	Host factors	Clinical evidence	Culture and its source	Histological evidence	PCR (copies/ml)	GM (O.D.L)	BDG (ng/ml)
1	41	F	P	AML M1	Post-allo, RD	Dead	NF	Erosion of sinus walls	A. flavus and A. fumigatus from pharyngeal mucosa	Biopsy	2,000/200	3.8/3.6	19.7/4.7
2	32	M	P	MDS (RAEB-t)	Post-allo, CR	Dead	GS	Dyspnea, pleural effusion		Autopsy	32/0	1.3/1.0	60.5/36.5
3	58	M	P	AML M1	RD	Dead	NF	Halo sign		Autopsy	90/42.5	7.7/6.4	25/1.5
4	38	F	P	AML M2	Post-allo, CR	Alive	NS	Cavity within area of consolidation	A. fumigatus from broncheal lavage fluid	Biopsy	33.5/0	1.9/1.7	2.8/0
5	51	M	P	Macroglobulinemia	Stable disease	Dead	None	Extensive skull base destruction	A. fumigatus from epidural abscess	Biopsy	0/0	1.2/0.8	37.4/7.1
6	19	M	P	MDS RA	RD	Dead	NF	Multiple nodular lesions in the lung field, pleural effusion		Autopsy	3,500/1,000	2.5/1.5	155.5/59.2
7	42	M	P	MDS/AML	Post-allo, RD	Dead	NFG	Dyspnea, pleural effusion		Autopsy	24/9	2.4/0.6	0/0
8	63	F	P	ATL acute type	RD	Dead	NF	Dyspnea, pleural effusion		Autopsy	50/12.5	1.9/0.7	2.4/0
9	69	M	P	ALL PreB	RD	Dead	NF	No specific clinical evidence		Autopsy	100,000/5,000	4.2/1.1	171.7/12.6
10	53	M	PP	AML M2	Post-allo, CR	Dead	FG	Dyspnea, pleural effusion	A. spergillus spp. from broncho- alveolar lavage fluid	NA^b	5/0	5.3/0.7	4.5/2.2
11	40	M	PP	CML CP1	Post-allo, CR	Alive	NGS	Halo sign	A. fumigatus from sputum	NA	11.5/7.5	2.3/2.0	0/0
12	68	M	PPP	MDS/AML	RD	Dead	NF	Multiple nodular lesions in the lung field, intraparenchymal brain mass lesion, seizure, hemiparesis		NA	155/100	2.2/1.5	18.3/16.6
13	24	M	PPP	AML M4E	CR, HDAraC	Alive	NF	Nodular skin lesion without any other explanation, multiple nodular lesions in the lung field		NA	20.5/0	4.5/0.3	0/0
14	61	M	PPP	AML M4E	CR, HDAraC	Alive	N	Halo sign		NA	1,000/9	0.2/0.1	3.5/2.9
15	30	M	PPP	ALL precursor B	Post-allo, CR	Alive	NFGS	Nonspecific abnormal shadow in lung field, pleural effusion		NA	60/60	0.6/0.4	0/0
16	61	M	PPP	AML M2	RD	Dead	NF	Multiple nodular lesions in the lung field, halo sign, cavity within area of consolidation		NA	84.5/0	1.1/0.7	2/0
17	68	M	PPP	CML BC	RD	Dead	NS	Dyspnea, pleural effusion		NA	165/0	0.3/0.2	0/0
18	25	M	PPP	ALL precursor B	RD	Alive	NG	Cavity within area of consolidation		NA	400/0	0.7/0.6	3.2/0
19	32	M	PPP	ALL PreB	Post-allo, CR	Dead	FGS	Dyspnea, pleural effusion		NA	27/1	0.7/0.5	3.7/2.4
20	18	F	PPP	AML M2	CR, HDAraC	Alive	N	Halo sign		NA	0/0	0.6/0.1	0/0
21	55	M	PPP	MDS RA	Stable disease	Alive	F	Cough, dyspnea, pleural effusion		NA	19/4	0.8/0.3	0/0
22	28	M	PPP	CML CP1	Post-allo, CR	Alive	G	Cough, dyspnea, pleural effusion		NA	0/0	0.4/0.3	0/0
23	40	M	PPP	CML CP1	Post-allo, CR	Alive	GS	Cough, dyspnea, new infiltrate not fulfilling the major radio- logical criteria without an alternative diagnosis		NA	6/0	0.5/0.4	0/0
24	54	M	PPP	ALL precursor B	Post-allo, CR	Alive	F	Dyspnea, new infiltrate not ful- filling the major radiological criteria without an alternative diagnosis		NA	10.5/0	0.5/0.3	0/0

F, female; M, male; P, proven; PP, probable; PPP, possible; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; RA, refractory anemia; RAEB-t, RA with excess of blasts in transformation; ALL, acute lymphoblastic leukemia/lymphoma; CML, chronic myelogenous leukemia; CP, chronic phase; BC, blastic crisis; allo, allogencic hematopoietic stem cell transplantation; CR, complete remission; RD, refractory disease; HDAraC, high-dose cytrabine; N, neutropenia; F, persistent fever; G, GVHD, S, prolonged use of corticosteroid.

NA, not available.